Lead Product(s) : Islasertib,Dofetilide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Thryv Receives FDA Orphan Designation for LQT-1213 in Long QT Syndrome
Details : LQT-1213 is a novel, first-in-class SGK1 inhibitor that the USFDA granted Orphan Drug Designation for the treatment of Long QT Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 01, 2024
Lead Product(s) : Islasertib,Dofetilide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
